- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Assessing the Economic Burden of Under Diagnosed Dry Eye Disease
Key opinion leaders highlight the importance of identifying and treating dry eye disease to mitigate long-term economic burdens.
EP: 1.Overview of Dry Eye Disease (DED) Causes and Treatments
EP: 2.Adverse Events & Existing Treatment Options for Dry Eye Disease
EP: 3.Navigating Different Subtypes of Dry Eye Disease
EP: 4.Assessing Efficacy of Treatment Through Patient-Reported Outcomes
EP: 5.Updating Formularies: Considerations for Dry Eye Disease
EP: 6.Assessing the Economic Burden of Under Diagnosed Dry Eye Disease
EP: 7.Identifying Key Socioeconomic Burdens Associated with Dry Eye Disease
EP: 8.Resource Allocation in the Treatment of Dry Eye Disease
EP: 9.Quality of Life & Patient Reported Outcomes in Dry Eye Disease
EP: 10.Annual Health Care Costs of Managing Dry Eye Disease
EP: 11.Novel Treatments Targeting Symptoms & Causes of Dry Eye Disease
EP: 12.Evaluating Treatment Outcomes in Dry Eye Disease
EP: 13.Evaluating Economic Impact of Emerging Therapies for Dry Eye Disease
EP: 14.Concluding Thoughts on the Treatment of Dry Eye Disease
This is a video synopsis/summary of a Stakeholder Summit involving:
Ryan Haumschild, PharmD, MS, MBA; Jai G. Parekh, MD, MBA; and Alexander Kabiri, OD.
Kabiri estimates over 35 million Americans have undiagnosed or untreated dry eye disease (DED). With growing prevalence from aging demographics and digital device use, costs of uncontrolled DED will likely mushroom. Only a small subset of identified DED patients receive prescription therapy, representing huge unmet need.
Parekh notes the uncontrolled impact of DED on visual function and economic burden is comparable to retinal disease and glaucoma. Even after otherwise successful cataract surgery, residual DED impairs outcomes. Growing prevalence with prolonged device use raises the societal impact of DED. Comprehensive payer coverage and peer education around the rising prominence of DED will be key.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More
Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status
February 18th 2025In patients with early-stage ovarian cancer, a high prognostic nutritional index improved survival, while a high systemic immune-inflammation index worsened it. In advanced stages, both affected overall survival but not progression-free survival.
Read More
